The hepatology community can contribute to the WHO goals of viral hepatitis elimination. Many countries, including the U.S., appear not to be on track to meet elimination targets by 2030. However, the US and other countries are taking steps to eliminate hepatitis.  Sharing lessons learned, including those resulting from the response to COVID-19, builds capacity for advancing progress toward hepatitis elimination. Understanding the unique successes and challenges in diagnosis, linkage to care and treatment for hepatitis B versus hepatitis C is important.

This symposium will present advances in the cure of HCV, including approaches in distinct patient populations. Some patients require minimal medical intervention and can achieve optimal results with simplified strategies, while others need more intensive interventions, such as treatment of concurrent substance-use disorder or HCV drug resistance. Learn the most effective strategies to eliminate HCV.

Discuss new advances in the management of liver masses at this symposium. The first talks cover the evaluation and diagnosis of liver lesions, and advances in locoregional therapy for HCC. Faculty will then review curative options for HCC, including surgical resection, liver transplantation, ablative techniques, and first- and second-line systemic chemotherapy, along with new clinical trial outcomes.

More than ever, social media is the landscape where hepatologists in clinical practice, academic medicine and research debate issues and share new insights. Patients also use social media to research their conditions and treatments. Get up to date on savvy, safe use of all social media platforms to advance the science and practice of hepatology at this lively session.

Review key highlights from all the exciting clinical research presented at The Liver Meeting® this year at this condensed round-up session, which is designed to complement the highly regarded Basic, Hepatitis and Clinical Hepatology Debriefs.

Explore innovative management strategies for pediatric patients with autoimmune liver diseases at this exciting symposium. Faculty will review the pathophysiology, diagnosis, management, and risk stratification of pediatric AIH and PSC. Talks will focus on diagnosis, primary and secondary lines of therapy, complex cases, pediatric-specific predictive models, and post-transplant disease recurrence. Preliminary results of recent clinical trials will be objectively presented.

Blood coagulation in drug-induced liver injury (DILI) is an emerging hot topic in basic and clinical research, and clinical practice. Physicians and basic scientists will review recent discoveries in molecular and cellular mechanisms of DILI blood coagulation, optimal clinical management of patients with acute and chronic liver diseases, and experimental animal models on Von Willebrand factor and platelets in DILI.

Don’t overlook any of the research presented at The Liver Meeting® 2021 that directly impacts patients. This year's debrief will briefly review of all the abstracts presented at the meeting that significantly impacted the role of the patient in one condensed session.

This presentation will discuss emerging concepts in our understanding of the pathogenesis of alcohol related hepatotoxicity and how it could inform therapeutic approaches.

There is a growing awareness that behavioral health interventions can improve outcomes for patients with chronic liver disease (CLD). This seminar examines the role of behavioral health in CLD care, existing disparities in behavioral health care access, and proposed plans to integrate these interventions and overcome care gaps to improve the health and well-being of CLD patients.